Want to see TSE:BU full AI Analyst Report?
BU Stock Chart & Stats
C$1.70
C$0.25(14.71%)
At close: 4:00 PM EDT
C$1.70
C$0.25(14.71%)
Day’s Range― - ―
52-Week RangeC$1.51 - C$2.99
Previous CloseN/A
Volume4.94K
Average Volume (3M)6.58K
Market Cap
C$23.61M
Enterprise ValueC$48.93
Total Cash (Recent Filing)C$950.53K
Total Debt (Recent Filing)C$24.42M
Price to Earnings (P/E)―
Beta0.41
Next Earnings
Aug 17, 2026EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.11
Shares Outstanding12,692,942
10 Day Avg. Volume9,144
30 Day Avg. Volume6,578
Financial Highlights & Ratios
PEG Ratio-0.29
Price to Book (P/B)-4.05
Price to Sales (P/S)10.37
P/FCF Ratio-2.32
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.16
Revenue Forecast (FY)C$14.00M
Bulls Say, Bears Say
Bulls Say
IP-driven Licensing Business ModelA licensing- and JV-focused model leverages Burcon’s proprietary extraction and purification IP to scale through partners rather than capital-intensive own manufacturing. This reduces fixed-capex burden, enables faster market reach via licensees, and supports recurring fee/royalty economics if adoption expands.
Commercial Traction And PipelineA broad pipeline with 200+ projects and 30+ buyers signals validated customer interest across multiple applications. Durable structural benefit: diversified early-adopter base reduces single-customer dependency and raises likelihood of steady licensing, repeat orders, and scale-driven revenue growth over the next several quarters.
Production Scale Progress And Quality ControlsThird-party certification and sizable production uplift demonstrate operational credibility and improved unit economics potential. Certification reduces customer validation friction for food customers, while sustained production gains support the company’s ability to meet commitments and expand commercial volumes sustainably.
Bears Say
Deteriorated Balance Sheet And LeverageRapidly rising debt and negative shareholder equity materially weaken financial flexibility and increase refinancing risk. Over the medium term, higher leverage limits ability to fund scaling investments, raises interest burden, and makes the company more vulnerable to execution hiccups or slower revenue realization.
Persistent Negative Cash GenerationSustained operating and free cash outflows signal ongoing burn to fund commercialization. Without durable positive cash generation or committed non-dilutive funding, the firm faces repeated financing needs that can dilute returns and constrain long-term investment in capacity, R&D, and customer support.
Early-stage Revenue And Profitability ShortfallDespite sharp percentage growth, the small absolute revenue base and negative gross margin imply the business model has not yet achieved sustainable unit economics. Combined with lengthy 9–18 month customer adoption cycles, profitability depends on successful scale-up and margin improvement that remain uncertain near term.
Burcon Nutrascience News
BU FAQ
What was Burcon Nutrascience’s price range in the past 12 months?
Burcon Nutrascience lowest stock price was C$1.51 and its highest was C$2.99 in the past 12 months.
What is Burcon Nutrascience’s market cap?
Burcon Nutrascience’s market cap is C$23.61M.
When is Burcon Nutrascience’s upcoming earnings report date?
Burcon Nutrascience’s upcoming earnings report date is Aug 17, 2026 which is in 15 days.
How were Burcon Nutrascience’s earnings last quarter?
Burcon Nutrascience released its earnings results on Jun 24, 2026. The company reported -C$0.3 earnings per share for the quarter, missing the consensus estimate of -C$0.1 by -C$0.2.
Is Burcon Nutrascience overvalued?
According to Wall Street analysts Burcon Nutrascience’s price is currently Overvalued.
Does Burcon Nutrascience pay dividends?
Burcon Nutrascience does not currently pay dividends.
What is Burcon Nutrascience’s EPS estimate?
Burcon Nutrascience’s EPS estimate is -0.07.
How many shares outstanding does Burcon Nutrascience have?
Burcon Nutrascience has 12,692,942 shares outstanding.
What happened to Burcon Nutrascience’s price movement after its last earnings report?
Burcon Nutrascience reported an EPS of -C$0.3 in its last earnings report, missing expectations of -C$0.1. Following the earnings report the stock price went down -16.594%.
Which hedge fund is a major shareholder of Burcon Nutrascience?
Currently, no hedge funds are holding shares in TSE:BU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Burcon Nutrascience
Burcon NutraScience Corporation (BU) is a plant-protein ingredients company focused on developing and commercializing specialty protein and protein-related ingredients for the food and beverage sector. The company’s core activity centers on patented and proprietary processes to extract and purify proteins from plant sources (notably canola/rapeseed and peas) for use in consumer packaged goods and other food applications that require functional and nutritional protein ingredients.
BU Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized strong operational progress and accelerating commercial traction — material revenue growth (nearly sixfold YoY), expanding customer pipeline (200+ projects and 30+ active buyers), repeat orders, and significant production improvements (60% higher daily production). Management also demonstrated cost discipline (G&A -23%, R&D -65%) and secured partial financing with partner and insider support. Primary challenges are the small absolute revenue base ($2.3M), remaining facility capital work and capacity planning, lengthy customer adoption cycles (9–18 months), and ongoing liquidity/financing considerations. Overall, the positive operational momentum and validated customer demand outweigh the early-stage risks and financing needs, but execution against scaling and profitability targets remains critical.View all TSE:BU earnings summaries